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Purpose: To identify human transient receptor potential cation channel, subfamily M, member 1 (TRPM1) gene mutations
in patients with congenital stationary night blindness (CSNB).
Methods: We analyzed four different Japanese patients with complete CSNB in whom previous molecular examination
revealed no mutation in either nyctalopin (NYX) or glutamate receptor, metabotropic 6 (GRM6). The ophthalmologic
examination included best-corrected visual acuity, refraction, biomicroscopy, ophthalmoscopy, fundus photography,
Goldmann kinetic perimetry, color vision tests, and electroretinography (ERG). Exons 2 through 27 and the exon-intron
junction regions of human TRPM1 were sequenced.
Results: Five different mutations in human TRPM1 were identified. Mutations were present in three unrelated patients
with complete CSNB. All three patients were compound heterozygotes. Fundus examination revealed no abnormalities
other than myopic changes, and the single bright-flash, mixed rod-cone ERG showed a “negative-type” configuration with
a reduced normal a-wave and a significantly reduced b-wave amplitude. Our biochemical and cell biologic analyses suggest
that the two identified IVS mutations lead to abnormal TRPM1 protein production, and imply that the two identified
missense mutations lead to the mislocalization of the TRPM1 protein in bipolar cells (BCs).
Conclusions: Human TRPM1 mutations are associated with the complete form of CSNB in Japanese patients, suggesting
that TRPM1 plays an essential role in mediating the photoresponse in ON BCs in humans as well as in mice.
The  complete  form  of  congenital  stationary  night
blindness (CSNB) is a subtype of Schubert-Bornschein CSNB
in which the fundus is essentially normal except for myopic
changes [1-5]. From early childhood, patients with complete
CSNB  lack  rod  function  and  experience  night  blindness.
Nystagmus and amblyopia sometimes accompany the other
symptoms,  and  the  clinical  course  is  stationary.  Best-
corrected  visual  acuity  is  mildly  reduced,  and  high  to
moderate myopia is usually found. Electroretinogram (ERG)
examinations reveal absent depolarization of neuron by light
(ON)-responses (b-wave), and previous extensive physiologic
studies indicated that the pathology in complete CSNB lies in
the dysfunction of the depolarizing ON bipolar cell (BC).
There are two hereditary patterns for complete CSNB: X-
linked recessive and autosomal recessive [4].
To  date,  two  genes,  the  leucine-rich  proteoglycan
nyctalopin  gene  (NYX)—encoding  the
glycosylphosphatidylinositol  (GPI)-anchored  extracellular
protein nyctalopin [6,7]—and the GRM6 gene—encoding the
metabotropic  glutamate  receptor  mGluR6—have  been
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identified  as  the  mutated  gene  in  X-linked  recessive  and
autosomal  recessive  complete  CSNB  [8-10],  respectively.
Both nyctalopin and mGluR6 proteins are distributed on the
postsynaptic ON BCs and are required for the depolarization
of the cell. The NYX gene appears to be the major, and possibly
only, causative gene for X-linked recessive complete CSNB
since NYX gene mutations were identified in the majority of
X-linked recessive families with complete CSNB. In contrast,
GRM6 gene mutations have been found in only some of the
autosomal recessive families with complete CSNB, indicating
the existence of other unknown genes for autosomal recessive
complete CSNB.
We  previously  identified  a  mouse  transient  receptor
potential cation channel, subfamily M, member 1 (Trpm1)
homolog  of  human  TRPM1  [11].  Trpm1  is  alternatively
spliced, resulting in the production of a long form protein
(trpm1-L)  and  a  short  N-terminal  form  devoid  of
transmembrane segments (trpm1-S). Although mouse trpm1-
S was previously identified as melastatin [12], mouse trpm1-
L has not been identified. Without distinction between trpm1-
L or trpm1-S, trpm1 has been reported to be detected in human
primary melanocytes [13], poorly metastatic melanoma cell
lines [14,15], mouse retinal pigment epithelium (RPE) [16],
and subsets of ON and hyperpolarization of neuron by light
(OFF) BCs [17,18]. We found that trpm1-L localization is
developmentally restricted to the dendritic tips of ON BCs in
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425co-localization  with  mGluR6  [11,19].  Trpm1  null  mutant TABLE 1. THE PRIMER SETS USED IN THIS STUDY.
Exon Direction Primer sequence (5′-3′)
2 Forward GCTTGGGAATGTATTGGTCC
2 Reverse TTCTGGACTCCTCTTTCTGC
3–1 Forward TTGCTAATGAAGGGGAAAGG
3–1 Reverse TGAAAGCTGTGATCCTAGTG
4–2 Forward TACCCAACAGATTCCTATGG
4–2 Reverse TTGTGGATTCAGAGCTTTGG
4 Forward TGCTTGGACATGAGCAATAG
4 Reverse TATTAGGAAGCTCTTTGGGG
5 Forward GATCTGTAGGGAATGTAGGG
5 Reverse CAACTGCATCTGAATCAACG
6 Forward TATTGTGCTTGCTTCCCTTG
6 Reverse GCAATCAATCTCCTTCTCAG
7 Forward TACTCTTCCCCATACTTCAG
7 Reverse CGTTTGGAATGTCTAAGCAG
8 Forward CCACAGCAAAGTCTCAAATC
8 Reverse AATAACCCTGTCATGCACAC
9 Forward CAGTCTCTGTGGTCATTTTG
9 Reverse TTCATGCTGAGACTGCTCAAG
10 Forward AAGCCAGCAATGCTTAGTTC
10 Reverse TGTCACAAGGGAGAACATAC
11 Forward ATGTGTGCACATACAGAGGT
11 Reverse GAAGCAAGGACAAGAACCAT
12 Forward ACCCTTTCCTCTGTGTTTCC
12 Reverse GCACAATATGCACCAGTGAC
13 Forward TACTGACCTCAAGTGATCTG
13 Reverse TTCATTATCTCCTGTGCCTG
14 Forward CTGTTACATGAACTCCCAAG
14 Reverse TTGTTGAAAAGCAAGCGAGG
15 Forward CCATTCGTATGTCCACTATC
15 Reverse GAGTAGTATCGTATATTCGC
16 Forward AGTTCTGGAACTCTTTGTTG
16 Reverse AGAGACAAGTACTCAGGATG
17 Forward GGTGGATATGCCTGTCTAAG
17 Reverse AAAGTGCTCAGTTCAGCCTG
18 Forward GGCTCCTAGGTTATTGAATA
18 Reverse GTGGTACAAGAAATCTCAAC
19 Forward TTCTAATGGTGCCTGTGTGC
19 Reverse CAATGTTAGCCAGAGATCTC
20 Forward GTGTCAACCTGAAAGAAAAC
20 Reverse TTTCAGTAAGGAGCCATATC
21 Forward ATGACCTGGAATGTTCCATC
21 Reverse GCCTGTTCTTATGTCCTAAC
22 Forward TATAATGAGCCAGGGTGAAC
22 Reverse TTTGGAACTGATCATCTGCC
23 Forward CTTTTCTCTCAACCATCATC
23 Reverse ACAGTGAATTTGTGGTTCTC
24 Forward AGCTGGGGCTACAGAGTTTA
24 Reverse TATCTTGGGAGCGTTCTGAG
25 Forward GTAACTTTGACTGCTCTGGG
25 Reverse CGAGCAAGTAGTTGAGTGAG
26 Forward GGGCTGTGAAATTCTCATTG
26 Reverse AACTCTGGCATCCCCCATAG
27–1 Forward CATGTTAGGGGATTGTGAAG
27–1 Reverse ATACGTTGCCTCACATTCAG
27–2 Forward CAGAATGGTGAATGCTCTTG
27–2 Reverse GAAAGGTGAAGACTGTTCTG
27–3 Forward AAAAAAACCTGTTCCTTCCG
27–3 Reverse TTTGTCGTTTCCACTGTTAG
27–4 Forward GAAGAAACTATTTCCCCAAG
27–4 Reverse GAATATCTGTGCTATGAGAG
27–5 Forward TAGAGTACAGTTCAATCACG
27–5 Reverse ATGGATTTCACATTCCTAGG
27–6 Forward TCTGTGAAGCCAGATCAAAC
27–6 Reverse GTTTAGATGGCCAAGATGAC
mice completely lose the photoresponse of ON BCs. Trpm1-
L channel activity is negatively regulated by activated Go in
the  mGluR6  cascade,  and  we  showed  that  Trpm1-L  is  a
component of the ON BC transduction channel. Interestingly,
the trpm1-deficient mice showed similar electrophysiological
responses to the responses of those with complete CSNB—
significantly  reduced  b-waves—which  led  us  to  examine
whether the gene is mutated in human patients with complete
CSNB.
Very recently three groups reported the association of
TRPM1 mutations with CSNB [20-22]. Independently from
these studies, in our present study, we identified five different
novel mutations in the human TRPM1 gene: IVS2–3C>G,
IVS8+3_6delAAGT,  R624C  (c.1870C>T),  S882X  (c.
2645C>A),  and  F1075S  (c.3224T>C).  In  addition,  our
biochemical and cell biologic analyses suggested that the two
intron mutations were likely to result in abnormal protein
production  by  abnormal  splicing,  and  the  two  missense
mutations lead to the mislocalization of the TRPM1 protein
in BCs. Fundus examination revealed no abnormalities other
than myopic changes, and the single bright-flash, mixed rod-
cone ERG showed a “negative-type” configuration with a
reduced normal a-wave and a significantly reduced b-wave
amplitude.
METHODS
Subjects: Four separate patients with complete CSNB (#204,
#373,  #437,  and  #484)  in  whom  previous  molecular
examination revealed no mutation in either NYX or GRM6
among 11 separate patients were analyzed. They were all
male, and their ages were 26, 9,19, and 27 years, respectively.
They complained of night blindness from early childhood, and
otherwise had no health problems. All individuals examined
had  been  under  observation  at  the  Department  of
Ophthalmology of Nagoya University, Nagoya, Japan. The
research  protocol  was  designed  in  compliance  with  the
Declaration  of  Helsinki  and  approved  by  the  institutional
review board. Written informed consent was obtained from
the subjects after an explanation of the purpose of this study
was provided. Briefly, the protocol entails molecular analysis
of  causative  genes  from  blood  samples  of  patients  with
complete CSNB and in vitro analysis including expression
assay and cytological assay using the samples without any
disadvantages for the patients.
DNA  analysis  of  patients  with  complete  CSNB:  Genomic
DNA was extracted from the peripheral blood leukocytes.
Exons 2 through 27 of TRPM1 were amplified by polymerase
chain reaction (PCR) using the DNA Thermal Cycler 9700
(Applied  Biosystems,  Foster  City,  CA).  Primers  were
designed by and purchased from Invitrogen (Carlsbad, CA).
The primer sets used in this study are shown in Table 1. For
all exons, 100 ng of genomic DNA was amplified in a 50 µl
reaction with 0.5 µM of each primer, 0.2 mM of each dNTP,
and AmpliTaq Gold polymerase (Applied Biosystems). The
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426PCR conditions were as follows: 5 min at 94 °C; 35 cycles at
94 °C for 30 s, followed by 30 s at 54 °C, and 45 s at 72 °C;
and a final extension step at 72 °C for 7 min. The PCR products
were directly sequenced using an ABI PRISM 3100 Genetic
Analyzer (Applied Biosystems) and BigDye Terminator v3.1
Cycle Sequencing Kit (Applied Biosystems). To search for
polymorphisms, exons 3, 8, 16, 21, and 24 of TRPM1 from
200 alleles (50 men and 50 women) from unrelated, normal
Japanese individuals were directly sequenced.
TRPM1  splicing  minigene  constructs:  DNA  fragments  of
TRPM1  exon  2  with  its  downstream  splice  donor  region
(nucleotide  position  in  GenBank  #  NC_000015:  24738–
25055; exon 2+SD) and exon 8 with its downstream splice
donor  region  (39020–39392;  exon  8+SD)  were  PCR-
amplified using human genomic DNA as a PCR template;
SacI and KpnI sites were appended to the 5′ and 3′ ends,
respectively. A partial fragment of β-globin (HBB) intron 2
(614–1166 in GenBank # NC_000011) was PCR-amplified;
KpnI and SalI sites were appended to the 5′ and 3′ ends,
respectively.  DNA  fragments  of  TRPM1  exon  3  with  its
upstream splice acceptor region (31325–31691; SA+exon 3)
and exon 9 with its splice acceptor region (39976–40280; SA
+exon 9) were PCR-amplified using human genomic DNA as
a PCR template; SalI and BamHI sites were appended to the
5′ and 3′ ends, respectively. The exon 2+SD, HBB intron, and
SA+exon 3 fragments (exon 2+3 construct), or exon 8+SD,
HBB intron, and SA+exon 9 (exon 8+9 construct) were ligated
and subcloned into the SacI and BamHI sites of pBluescript
KS+ (Stratagene), containing three repeats of the Flag-tag
between the BamHI and NotI sites. The generated exon 2+3
construct and exon 8+9 construct were digested with SacI and
NotI and subcloned into SacI and BamHI digested pEGFP-C3
and pEGFP-C2 (Clontech, Palo Alto, CA), respectively, each
with a synthesized BglII-NotI linker.
Transfection and western blots analysis: HEK293T cells were
cultured in D-MEM containing 10% fetal bovine serum (FBS;
Nissui, Tokyo, Japan). These cells were grown under 5%
carbon dioxide at 37 °C. Transfections were performed using
the  calcium  phosphate  method.  Transfected  cells  were
incubated at 37 °C for 48 h, and harvested for further analysis.
Cell  extract  proteins  were  separated  by  SDS–PAGE,  and
transferred to a polyvinylidene difluoride membrane (ATTO,
Tokyo Japan). The membrane was incubated with a mouse
anti-Flag antibody (1:1,000; Sigma, St Louis, MO), a rabbit
anti-β−gal antibody (1:10,000; Chemicon, Temecula, CA), or
a  mouse  anti-β−actin  antibody  (1:2,000;  Sigma),  and
incubated with a horseradish peroxidase-conjugated goat anti-
mouse or -rabbit IgG (1:10,000; Zymed Laboratories, San
Francisco, CA). The bands were visually developed using
Chemi-Lumi One L (Nacalai Tesque, Kyoto, Japan).
In vivo electroporation and section immunohistochemistry:
In vivo electroporation was performed at postnatal day 0 (P0)
as described previously [23]. Approximately 0.3 μl of DNA
solution (5 μg/μl) was injected into the subretinal space of P0
mouse pups, and square electric pulses (80 V; five 50 ms
pulses with 950 ms intervals) were applied with electrodes.
Wild-type (WT) and mutant forms of TRPM1 (R624C and
F1075S) containing 3× Flag at the C-terminus were expressed
from  the  mouse  mGluR6  promoter  (mGluR6-TRPM1–
3×Flag). To generate this construct, the chicken β-actin gene
(CAG) promoter region in CAG-TRPM1 was replaced with
the 9.5 kb fragment of mGluR6 5′ upstream genomic sequence
[24].  mGluR6-TRPM1–3×Flag  (4  μg/μl)  and  CAG-GFP
(1  μg/μl)  were  co-electroporated  and  harvested  at  P14.
Immunohistochemistry to observe the subcellular localization
of TRPM1–3×Flag expressed in the electroporated ON BCs
was  performed  on  sections  as  previously  described  [23].
Mouse anti-Flag antibody (1:500), rabbit anti-PKCα antibody
(1:20,000;  Sigma),  and  rat  anti-GFP  antibody  (1:1,000;
Nacalai  Tesque)  were  used.  The  signal  intensity  of  Flag
immunostaining at the dendritic tips and somas of ON BCs
was  measured  using  AxioVision  software  (Carl  Zeiss,
Oberkochen,  Germany).  The  ON  BCs  that  showed  more
intensity in the dendritic tips than in the somas were counted.
One hundred electroporated ON BCs were counted from three
retinas independently prepared for each construct.
Clinical  evaluations  in  patients  associated  with  TRPM1
mutations: The ophthalmologic examination included best-
corrected  visual  acuity,  refraction,  biomicroscopy,
ophthalmoscopy,  fundus  photography,  Goldmann  kinetic
perimetry, color vision testing, and electroretinography [25].
Standardized  full-field  ERGs  were  elicited  by  Ganzfeld
stimuli after pupillary dilation with 0.5% tropicamide and
0.5%  phenylephrine  hydrochloride  and  20  min  of  dark-
adaptation. The rod (scotopic) ERGs were elicited by a blue
stimulus with a luminance of 5.2×10−3 cd/sec•m2. The mixed
rod-cone, single flash (bright white) ERGs were elicited by a
white stimulus of 44.2 cd/sec•m2. The photopic (cones) single-
flash ERGs and 30 Hz flicker ERGs were elicited by white
stimuli  at  a  luminance  of  4  cd/sec•m2  and  0.9  cd/sec•m2,
respectively, on a white background of 68 cd/m2. The single
flash bright white ERGs were recorded again after 17 h of dark
adaptation.
ERG recordings in the trpm1 null mutant (trpm1–/–) mice: We
generated trpm1–/– mice as described previously [11]. Our
methods for recording the ERGs from the mice have been
described in detail [26]. In brief, the mice were dark-adapted
overnight,  and  then  anesthetized  with  an  intramuscular
injection of 70 mg/kg ketamine and 14 mg/kg xylazine. ERGs
were recorded with a gold-wire loop electrode placed on the
anesthetized cornea. The mice were placed in a Ganzfeld bowl
and stimulated with stroboscopic stimuli of 1.0 log cd-s/m2
(photopic units) maximum intensity. Four levels of stimulus
intensity ranging from −5.0 to 1.0 log cd-s/m2 were used for
the dark-adapted ERG recordings, and four levels of stimulus
intensity ranging from −0.5 to 1.0 log cd-s/m2 were used for
the  light-adapted  ERGs.  The  light-adapted  ERGs  were
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cd-s/m2 (photopic units). The amplitude of the a-wave was
measured from the baseline to a set time of 8 msec after the
initial negative wave for the dark-adapted ERG, and 11 msec
for  the  light-adapted  ERG.  The  b-wave  amplitude  was
measured  from  the  negative  trough  of  the  a-wave  to  the
maximal positive peak.
Animal  care:  All  procedures  conformed  to  the  ARVO
Statement for the Use of Animals in Ophthalmic and Vision
Research,  and  these  procedures  were  approved  by  the
Institutional  Safety  Committee  on  Recombinant  DNA
Experiments and the Animal Research Committee of Osaka
Bioscience Institute. The mice were housed in a temperature-
controlled room with a 12h:12h light-dark cycle. Fresh water
and rodent diet were available at all times.
RESULTS
DNA analysis of the complete CSNB patients: Five different
mutations  in  TRPM1  were  identified:  IVS2–3C>G,
IVS8+3_6delAAGT,  R624C  (c.1870C>T),  S882X  (c.
2645C>A),  and  F1075S  (c.3224T>C).  Mutations  were
present  in  three  unrelated  patients  with  complete  CSNB
(#373, #437, and #484). All three patients were compound
heterozygotes.  Their  pedigrees  and  the  DNA  sequence
chromatogram for the patients harboring these mutations are
presented in Figure 1A,B.
The  two  intron  changes,  IVS2–3C>G  and
IVS8+3_6delAAGT  (Figure  1C),  were  interpreted  to  be
pathogenic because no RNA splicing activities were detected
when each of the two changes was present (see splicing assay
section). They were also predicted to affect RNA splicing, as
assessed by an online splice-site prediction tool. The donor
site prediction score from the software for the exon 8 donor
site in TRPM1 was 0.99 for the WT sequence, whereas it was
under 0.01 for the corresponding mutated sequence with the
IVS8+3_6delAAGT  sequence  change.  The  acceptor  site
prediction score for the exon 3 acceptor site in TRPM1 was
0.98 for the WT sequence, whereas it was 0.44 for the mutated
sequence with the IVS2–3C>G sequence change. The two
mutations were not found in an analysis of 100 Japanese
normal controls.
The S882X mutation was considered to be a pathogenic
null mutation since mRNA containing the predicted early stop
codon would most likely be subject to nonsense mediated
decay without being translated into a protein [27]. Even if the
translated protein was produced, it would lack the C-terminus
region of TRPM1, including transmembrane domains 4–6,
which is very likely to lead to a loss of function as a cation
channel (Figure 1D). This change was not found among the
100  healthy  control  individuals  we  examined.  The  two
missense changes in the TRPM1 gene, R624C and F1075S,
were located in the N-terminal region and in the C-terminal
end of the transmembrane domain, respectively (Figure 1D).
They  were  interpreted  as  likely  pathogenic  because  the
arginine at position 624 and the phenylalanine at 1075 are well
conserved  among  the  TRPM  subfamily,  suggesting  the
importance of these amino acid residues for TRPM function
(Figure 1E). The two mutations were not found in an analysis
of 100 Japanese normal controls. None of the five mutations
mentioned above have been reported in a SNP database.
Analysis  of  protein  expression  from  TRPM1  mutant
minigenes:  Our  previous  expression  analysis  of  mouse
TRPM1  showed  that  the  long  form  (TRPM1-L),  which
functions as a cation channel, is predominantly expressed in
the retina [11], suggesting that human patient samples for
directly  analyzing  splicing  are  not  readily  available.  To
overcome this limitation, minigenes for expression in tissue
culture cells were designed; these minigenes included the
upstream exons (exon 2 or 8) fused with EGFP, downstream
exons (exon 3 or 9) fused with 3×Flag-tags, and a HBB intron,
which is often used in splicing assays (an exon 2+3 minigene
and an exon 8+9 minigene; Figure 2A). Since the signals
required  for  constitutive  splicing  are  usually  within  ~100
nucleotides of splice junctions [11], we took ~200 nucleotide
regions for both splicing donors and acceptors to ensure the
splicing  assay.  We  also  generated  mutated  minigenes
containing  the  IVS2–3C>G  mutation  in  the  exon  2+3
minigene or the IVS8+3_6delAAGT mutation in the exon 8+9
minigene. Minigene splicing was analyzed in HEK293T cells
since they have been used extensively to study constitutive
RNA  splicing.  HEK293T  cells  were  transfected  with
minigene DNA and a lacZ expression internal control vector,
and western blotting was performed on whole cell extracts
isolated 48 h later. We then analyzed protein products of the
EGFP-exon  2+3  fusion  and  the  EGFP-exon  8+9  fusion
proteins  by  western  blot  analysis  of  whole  cell  extracts
transfected with the WT and mutated minigenes. We detected
an  expected  45  kDa  or  39  kDa  band  with  the  anti-Flag
antibody in HEK293T cell extracts transfected with the WT
exon 2+3 minigene or the exon 8+9 minigene (Figure 2B,C).
In contrast, we did not detect any bands in either of the cell
extracts transfected with the mutated minigenes. We detected
the β-gal bands of the transfection internal control, and the β-
actin bands of the cell extract control in both the WT and
mutant minigene transfected cells. These results showed that
both  the  IVS2–3C>G  and  IVS8+3_6delAAGT  mutations
abrogate  normal  splicing  and  lead  to  abnormal  protein
production, suggesting that these trpm1 alleles are loss-of-
function alleles.
In  vivo  analysis  of  intracellular  localization  of  TRPM1
protein carrying missense mutations: The TRPM1 missense
mutations R624C and F1075S are located in the N-terminal
and the C-terminal end of the six-transmembrane domains
(6TM), respectively (Figure 1D). Mutations in these regions
often cause misfolding/mislocalization of the protein, and/or
a  defect  in  channel  activity  [28-32].  To  determine  the
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428Figure 1. Compound heterozygous TRPM1 mutations identified in patients #373, #437, and #484. A: Sequence chromatograms showing the
mutations: IVS2–3C>G in patient #373 (a), IVS8+3_6delAAGT in patient #484 (b), Arg624Cys (c. 1870C>T) in patients #437 and #484 (c),
Ser882Ter (c. 2645C>A) in patient #437 (d), and Phe1075Ser (c. 3224T>C) in patient #373(e). B: Complete CSNB pedigrees of Japanese
patients #373, #437, and #484. These three patients are compound heterozygotes of TRPM1 mutations. C: Exon structures of human
TRPM1. The first methionine (Start) and a stop codon (Stop) of the TRPM1 open reading frame are indicated. All mutations found in this
study are shown. D: Putative topology of the human TRPM1. All mutations found in this study are illustrated. The six transmembrane domains
are indicated as TM1-TM6. E: Alignment of R624 and F1075 in TRPM proteins. Sequence alignment of TRPM1 from human, bovine, mouse,
chick, and TRPM2, TRPM4, and TRPM7 from human. Amino acid residues R624 and F1075 are boxed. The asterisks indicate completely
conserved residues.
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429functional relevance of R624C and F1075S TRPM1 residues,
we mutagenized the TRPM1 cDNA to introduce R624C and
F1075S  mutations.  We  first  prepared  expression  vectors
encoding R624C or F1075S mutant proteins attached with a
Flag-tag at the C-terminus, and expressed them both, as well
as WT vectors, in HEK293T cells. We did not observe a
significant difference in the protein level between the mutants
and  WT  by  western  blotting,  suggesting  that  the  protein
stability of R624C and F1075S was not affected (data not
shown). We then prepared expression vectors of R624C- and
F1075S-TRPM1 cDNAs fused with the mouse mGluR6 9.5 kb
promoter that drives ON BC-specific expression (Figure 3A).
We electroporated each of them as well as the WT vector into
the P0 mouse retinas. We examined the localization of the
Figure 2. Analysis of protein expression
from  TRPM1  mutant  minigenes.  A:
Schematic of TRPM1 minigenes. The
minigene  IVS2–3C>G  contains  an
EGFP gene, exon 2, the exon 2 splice
donor region, a portion of the β-globin
(HBB)  intron  2,  the  exon  3  splice
acceptor region, and exon 3, and uses the
CMV  promoter  and  SV40  polyA  site
from  the  pEGFP-C3  vector.  The
minigene IVS8+3_6delAAGT contains
an EGFP gene, exon 8, the exon 8 splice
donor  region,  a  portion  of  the  HBB
intron  2,  the  exon  9  splice  acceptor
region, and exon 9, and uses the CMV
promoter and SV40 polyA site from the
pEGFP-C2 vector. Mutations of IVS2–
3C>G  and  IVS8+3_6delAAGT  are
shown. B-C: western blots of HEK293
cell extracts transfected with minigenes
IVS2–3C>G  (B)  or
IVS8+3_6delAAGT  (C).  WT
represents  protein  from  a  wild-type
minigene  transfection,  and  asterisks
represent spliced EGFP detected by an
anti-Flag  antibody.  β-Gal  and  β-actin
were used for transfection control and
loading control, respectively.
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430expressed TRPM1 mutant proteins in ON BCs at P14 when
the endogenous mouse TRPM1 is preferentially localized to
the dendritic tips [11,19]. The electroporated human TRPM1
was visualized by an anti-Flag tag antibody. TRPM1 WT was
localized at the soma (arrow) and dendritic tips (arrowheads)
of  the  ON  BCs  (Figure  3B,C).  On  the  other  hand,  the
immunostaining signals of both the R624C and the F1075S
TRPM1 proteins were significantly weaker than those of the
WT protein (Figure 3D-G). We quantified the number of
electroporated ON BCs in which the WT TRPM1 protein was
localized more in the dendritic tips than somas. About 70% of
ON  BCs  that  electroporated  with  WT  TRPM1  showed  a
brighter TRPM1 signal at the dendritic tips, and the signals on
the dendritic tips were dramatically reduced in both mutant
proteins (Figure 3H). These results may imply that R624C and
F1075S mutations lead to mislocalization of TRPM1 protein
and are responsible for the protein trafficking of TRPM1
channel proteins. However, it should be noted that there is also
a  possibility  that  the  transfected  TRPM1  proteins  are
misfolded due to the addition of the 3xFlag tag, leading to the
undetectability of Flag-tagged mutant proteins specifically in
the  dendrites.  Future  analysis  is  required  to  obtain  a
conclusive result on this point.
Clinical  characteristics  of  the  complete  CSNB  patients
associated  with  TRPM1  mutations:  The  clinical
characteristics  of  the  three  complete  CSNB  patients  with
TRPM1 mutations are summarized in Table 2. All the patients
showed the typical clinical features of complete CSNB. They
complained of night blindness from their early childhood, and
the best-corrected visual acuities were normal in two patients
(#373  and  #437)  and  mildly  reduced  in  one  (#484).  The
refractive  errors  were  highly  or  moderately  myopic,  and
astigmatism was present in all of the patients (Table 2). Mild
nystagmus and esotropia was observed in the patient with
reduced visual acuity (#484). Slit lamp examination revealed
no  abnormality,  and  all  fundus  examinations  revealed  no
abnormalities in the posterior pole other than myopic changes,
including the tilted discs and temporal pallor of the optic discs
(Figure 4). Goldmann kinetic visual fields and color vision
tests  with  the  Ishihara  plates,  the  AO  H-R-R
pseudoisochromatic plates, and Farnsworth D-15 panel test
were conducted in two patients (#437 and #484) with normal
results. No family history was obtained from the patients
(Figure 1B).
The full-field scotopic (rod) ERGs elicited by a blue light
were non-recordable after 20 min of dark-adaptation (Figure
5B). The photopic ERG showed an a-wave with apparently
normal implicit time and a b-wave with delayed implicit time
(Figure 5C). The amplitudes of the 30 Hz flicker ERG were
within normal range (Figure 5D). The single bright-flash,
mixed  rod-cone  ERG  elicited  by  a  white  stimulus  had  a
“negative-type” configuration with a reduced normal a-wave
and with a significantly reduced b-wave amplitude (Figure
5A). The oscillatory potentials were reduced.
ERG analysis of the trpm1 null mutant (trpm1–/–) mice: To
address a possible role of TRPM1 in ON BC function, we
previously generated trpm1 null mutant (trpm1–/–) mice by
targeted  gene  disruption  [11].  Next,  to  compare  the
physiologic retinal function of trpm1–/– between humans and
mice, we recorded mouse ERGs in 8-week-old mice (Figure
6). The dark-adapted (rod) ERGs elicited by different stimulus
intensities from WT and trpm1–/– mice are shown in Figure
6A.  The  amplitudes  of  the  a-wave,  originating  from  the
photoreceptors, were approximately equal for both types of
mice (Figure 6B). In contrast, the dark-adapted ERG b-wave,
originating mainly from the ON BCs, in trpm1–/– mice was not
present at the lower intensities, and only a very small positive
inflection was seen at the highest stimulus intensity of 1.0 log
cd-s/m2 (Figure 6C). The ERGs elicited by different stimulus
intensities  from  light-adapted  WT  and  trpm1–/–  mice  are
shown in Figure 6D. The b-wave was severely depressed or
absent leaving only the a-wave in the trpm1–/– mouse (Figure
6E,F). These ERG results are similar to those obtained by
other groups [19,33], and suggested that the function of both
rod and cone ON BCs, and the signal transmission from rod
and cone photoreceptors to BCs were severely impaired in
trpm1–/– mice. In contrast, the presence of a normal a-wave
indicated  that  the  rod  and  cone  photoreceptors  were
functioning normally in this mutant mouse.
DISCUSSION
An  essential  step  in  intricate  visual  processing  is  the
segregation of visual signals into ON and OFF pathways by
retinal  BCs  [34].  The  release  of  glutamate  from
photoreceptors  modulates  the  photoresponse  of  ON  BCs
[35] via metabotropic glutamate receptor 6 (mGluR6) and the
G-protein (Go) that regulates a cation channel [36-38]. We
recently reported that we identified a mouse trpm1 long form
(trpm1-L)  and  found  that  TRPM1-L  localization  is
developmentally restricted to the dendritic tips of ON BCs in
co-localization with mGluR6 [11]. Trpm1 null mutant mice
completely lose the photoresponse of ON BCs. TRPM1-L
channel activity is negatively regulated by activated Go in the
mGluR6 cascade. These results suggest that TRPM1-L is a
component  of  the  ON  BC  transduction  channel.  These
observations led us to examine whether the gene is mutated
in human patients with complete CSNB in the current study.
To  identify  human  TRPM1  gene  mutations  in  CSNB
patients, we analyzed four separate Japanese patients with
complete CSNB in whom previous molecular examination
revealed no mutation in either the NYX or GRM6 genes. In the
current  study,  we  identified  five  different  mutations  in
TRPM1:  IVS2–3C>G,  IVS8+3_6delAAGT,  R624C  (c.
1870C>T), S882X (c.2645C>A), and F1075S (c.3224T>C).
Mutations  were  present  in  three  unrelated  patients  with
complete CSNB (#373, #437, and #484). Using a minigene
expression  assay,  we  showed  that  two  intron  mutations,
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431Figure 3. In vivo electroporation of WT,
R624C, and F1075S TRPM1 expression
vectors  fused  with  the  mGluR6
promoter. A: DNA constructs used for
electroporation.  CAG-GFP  was  co-
electroporated to identify electroporated
regions.  WT  and  mutant  forms  of
TRPM1  fused  with  3×Flag  were
expressed under the mouse mGluR6 9.5
kb  promoter.  B-G:  Section
immunohistochemistry  of  the  P14
retinas electroporated in vivo at P0 with
CAG-GFP  and  mGluR6-TRPM1–
3×Flag.  The  sections  were
immunostained with PKCα (blue), GFP
(green), and Flag (red) antibodies (B,
D, and F). Immunostaining with Flag
was visualized separately (C, E and G).
Arrows  represent  the  soma  and
arrowheads represent the dendritic tips
of  ON  BC.  Scale  bar:  10  μm.  H.
Composition of electroporated ON BC
(GFP+  PKCα+),  where  bright  Flag
signal  was  observed  in  the  dendrites.
The  error  bars  represent  standard
deviation (SD). Asterisks show that the
differences  are  statistically  significant
(n=3) (Student’s t-test, p<0.05).
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432IVS2–3C>  and  IVS8+3_6delAAGT,  can  cause  splicing
abnormalities leading to defects in protein production. Since
these two mutations are located in the N-terminus region of
TRPM1,  these  mutations  are  likely  to  produce  a  loss-of-
function allele of TRPM1. The nonsense mutation S882X (c.
2645C>A)  is  located  between  TM2  and  TM3.  Thus,  the
truncated TRPM1 protein is likely to be non-functional as a
channel. Regarding the two missense mutations, R624C (c.
1870C>T) and F1075S (c.3224T>C), we observed failure of
the transportation of the missense mutant channels to the
dendritic tips. However, ~20% of ON BCs could transport the
mutant forms of TRPM1, suggesting that these ON BCs are
still active. Considering that human patients carrying these
mutations still have cone ERG responses, this fraction might
be cone ON BCs converging inputs from cone photoreceptors.
Since  these  two  amino  acid  residues  are  evolutionarily
conserved among the TRPM subfamily, these amino acid
residues are indispensable for the physiologic functions of
TRPM  channels.  For  example,  R671Q  mutation  in  the
Drosophila TRPM1 homolog (trp14) resulted in a significant
reduction of ERG response [39]. This mutation is located
between the 6TM and the TRP domain [40], which is close to
the F1075 residue of human TRPM1. Although this region is
not in the functional domains, it still could be responsible for
the physiologic function of the TRPM channel.
The  scotopic  ERG  b-waves  recorded  using  Ganzfeld
stimuli were nonrecordable, and the photopic ERG showed
normal a-wave amplitude, but the amplitude of the b-wave is
reduced or absent in the three affected human individuals.
There  seems  to  be  no  apparent  genotype-phenotype
correlation in our patients with TRPM1 mutations. Full-field
ERG  results  showed  no  detectable  post-receptoral  ON-
pathway function for the three patients. The ERG amplitudes
of patient #484 were smaller than those of the other two
patients, but the reductions were considered to be due to high
myopia (−12 to −13 D) [41] or other unknown reasons. The
function of the inner retina was further analyzed using L-M
cone ERGs elicited by rectangular, 100–125 msec duration
light stimuli under light-adapted conditions in one patient, and
as a result, the amplitude of the b-wave at light onset (ON-
response) was significantly reduced, but the d-wave amplitude
(OFF-response) at light offset was unaffected with normal
TABLE 2. CLINICAL CHARACTERISTICS IN COMPLETE CSNB WITH TRPM1 MUTATIONS.
Mutation
Corrected
visual acuity Refraction
Color
vision
Fundus
appearance
Visual
field
Night
blindness Nystagmus Strabismus
patient #373 (Male, 9 years old)
IVS3–3C>G,
F1075S
1.0 (OD) −8.25 −2.75 X 40 (OD) ND Myopic ND + − Orthophoria
1.0 (OS) −8.25 −0.50 X 180 (OS)
patient #437 (Male, 19 years old)
R624C, S882X 1.0 (OD) −4.50 −2.25 X 120 (OD) Normal Myopic Normal + − Orthophoria
1.0 (OS) −4.50 −2.75 X 50 (OS)
patient #484 (Male, 27 years old)
IVS9+3_6delA
AGT, R624C
0.5 (OD) −13.00 −3.00 X 90 (OD) Normal Myopic Normal + + Esotropia
Figure 4. Fundus photographs of patients with mutations of TRPM1. A-C: Fundus images of patient #373 (A), patient #437 (B), and patient
#484 (C). All fundus examinations revealed no abnormalities in the posterior pole other than myopic changes, including the tilted discs and
temporal pallor of the optic discs. The patient’s number is indicated in each photograph.
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433OPs  on  the  OFF-responses  (data  not  shown).  These
electrophysiological results indicated that the pathology in
complete CSNB with TRPM1 mutations lay in the dysfunction
of the depolarizing ON BCs because it is generally considered
that  the  positive  ON-response  (b-wave)  reflects  the
depolarizing ON BCs. The impairment in the ON-response
was  also  observed  in  the  trpm1–/–  mice  in  which  b-wave
amplitude for both scotopic and photopic conditions were
completely  defective.  These  results  in  human  and  mice
strongly indicated that TRPM1 is essential for the function of
ON BCs in the visual pathway.
The clinical features of patients with complete CSNB are
similar  even  when  the  causative  gene  is  different.  Most
patients complain of night blindness while showing normal
fundi accompanied by highly myopic refractive errors [4,5].
The  best-corrected  visual  acuity  is  mildly  reduced,  or
sometimes normal. We could not clarify any difference in
ERG  responses  that  were  recorded  according  to  ISCEV
Figure  5.  Full-field  ERGs  of  patients
with mutations of the TRPM1 gene. A-
D: Full-field ERGs recorded in a normal
subject and three affected individuals.
The single bright-flash, mixed rod-cone
ERGs  showed  a  “negative-type”
configuration with a reduced normal a-
wave  and  a  significantly  reduced  b-
wave amplitude (A). The scotopic ERGs
showed  no  response  after  20  min  of
dark-adaptation  (B).  The  photopic
ERGs showed an apparent a-wave with
normal implicit time and a b-wave with
delayed  implicit  time  (C).  The
amplitudes of the 30 Hz flicker ERGs
were  within  normal  range  (D).  The
oscillatory  potentials  were  reduced.
Arrowheads:  stimulus  onset.  Each
patient’s number is noted at left.
Figure 6. ERG of WT and trpm1–/– mice.
A-F: ERGs recorded from 8-week-old
mice.  Dark-adapted  (A)  and  light-
adapted (D) ERGs were elicited by four
different stimulus intensities in both WT
and trpm1–/– mice (n=5). Amplitudes of
dark-adapted (B) and light-adapted (E)
ERG  a-waves  as  a  function  of  the
stimulus  intensity  are  shown.
Amplitudes  of  dark-adapted  (C)  and
light-adapted  (F)  ERG  b-waves  as  a
function  of  the  stimulus  intensity  are
shown. The bars represent the standard
error  of  the  mean  (SEM).  Asterisks
show that the differences are statistically
significant  (Mann–Whitney  test,
p<0.05).  The  trpm1–/–  mouse  had  a
normal a-wave, but a severely depressed
b-wave for both dark- and light-adapted
ERGs.
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434protocol among those with different gene defects. To date, the
only phenotypic difference among complete CSNB patients
with  different  gene  mutations  has  been  detected  using  a
scotopic 15 Hz-flicker ERG with increasing intensities [42].
It was reported that patients with TRPM1 mutations showed
15  Hz-flicker  ERG  responses  similar  to  those  with  NYX
mutations, but different from those with GRM6 mutations or
normal control subjects, suggesting some difference in the rod
pathway [21].
Very recent studies reported that TRPM1 gene mutations
were the major cause of AR complete CSNB in patients with
Caucasian ancestors [20-22]. We previously identified NYX
mutations  in  five  families  and  GRM6  mutations  in  two
families among 11 Japanese families with complete CSNB
[43,44], and in the current study, we found TRPM1 mutations
in three of the remaining four families. From these results we
confirmed that the gene was responsible for patients with
complete CSNB. It is likely that one of the three genes that is
localized  at  the  dendritic  terminals  of  ON  BCs  and
contributing the cell activity, TRPM1, GRM6, or NYX, would
responsible for most patients with complete CSNB.
In conclusion, we identified five different mutations in
the TRPM1 gene in three unrelated Japanese patients with
complete CSNB. TRPM1 is essential for the depolarizing ON
BC function in humans as well as in mice.
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